EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Running, not enrolling · Phase 4

Conditions studied: Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization

In brief

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]).

Key facts

Study ID
NCT05284747
Run by
Amgen
People needed
6019
Starts
2022-10-26
Expected to finish
2027-05-29
Last updated by the study team
2025-10-06

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.